Corrigendum to "Let's assume that hepatitis C reduces the cardiovascular risk in dialysis patients: Are there practical implications?" [J Hepatol 44 (2006) 837-838] (DOI:10.1016/j.jhep.2006.03.001);Let's assume that hepatitis C reduces the cardiovascular risk in dialysis patients: Are there practical implications?

Journal of Hepatology

Volumn 44, Issue 5, 2006, Pages 837-838

  Cattaneo, Dario ^a,b   Perico, Norberto ^a,b   Remuzzi, Giuseppe ^a,b  

^a OSPEDALI RIUNITI   (Italy)

^b Transplant Research Center   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CARDIAC PATIENT; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE COURSE; DYSLIPIDEMIA; EDITORIAL; HEMODIALYSIS; HEPATITIS C; HUMAN; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PERIPHERAL VASCULAR DISEASE; PREVALENCE; PRIORITY JOURNAL; STROKE; VIRAL CONTAMINATION;

EID: 33646493720     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.06.006     Document Type: Erratum

References (14)

1. Fehr T., and Ambuhl P.M. Chronic hepatitis virus infections in patients on renal replacement therapy. Nephrol Dial Transplant 19 (2004) 1049-1053
2. Green M, Avery RK. Viral hepatitis guidelines in hemodialysis and transplantation. Am J Transplant 2004;4:72-82.
3. Batty Jr. D.S., Swanson S.J., Kirk A.D., Ko C.W., Agodoa L.Y., and Abbott K.C. Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival. Am J Transplant 1 (2001) 179-184
4. Knoll G.A., Tankersley M.R., Lee J.Y., Julian B.A., and Curtis J.J. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis 29 (1997) 608-614
5. Stehman-Breen C.O., Emerson S., Gretch D., and Johnson R.J. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis 32 (1998) 629-634
6. Butt A.A., Evans R., Skanderson M., and Obaid Shakil A. Comorbid medical and psychiatric conditions and substance abuse in HCV infected persons on dialysis. J Hepatol 44 (2006) 864-868
7. Pockros P.J., Shiffman M.L., Schiff E.R., Sulkowski M.S., Younossi Z., Dietrich D.T., et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combinution therapy. Hepatology 40 (2004) 1450-1458
8. Loftis J.M., Matthews A.M., and Hauser P. Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management. Drugs 66 (2006) 155-174
9. Singh N., Gayowski T., Wagener M.M., and Marino I.R. Vulnerability to psychologic distress and depression in patients with end-stage liver disease due to hepatitis C virus. Clin Transplant 11 (1997) 406-411
10. Vassalle C., Masini S., Bianchi F., and Zucchelli G.C. Evidence for association between hepatitis C virus seropositivity and coronary artery disease. Heart 90 (2004) 565-566
11. Volzke H., Schwahn C., Wolff B., Mentel R., Robinson D.M., Kleine V., et al. Hepatitis B and C virus infection and the risk of atherosclerosis in a general population. Atherosclerosis 174 (2004) 99-103
12. Momiyama Y., Ohmori R., Kato R., Taniguchi H., Nakamura H., and Ohsuzu F. Lack of any association between persistent hepatitis B or C virus infection and coronary artery disease. Atherosclerosis 181 (2005) 211-213
13. Prichard S.S. Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol 9 (2003) S315-S320
14. Wanner C. Lipids in end-stage renal disease. J Nephrol 15 (2002) 202-204